Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Holmberg

Showing results (171-180 of 287) with videos related to

Pageof 29
Sort By:
BMJ Open|December 29, 2022
Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort studyMats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, et al.
British Journal of Haematology|July 14, 2007
Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpuraMinola Manea, AnnCharlotte Kristoffersson, Reinhard Schneppenheim, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Epidemiology (Cambridge, Mass.)|May 3, 2021
An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate CohortsRolf Gedeborg, Malin Sund, Mats Lambe, et al.
Ecancermedicalscience|February 20, 2018
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitusDanielle Crawley, Florence Chamberlain, Hans Garmo, et al.
BJU International|January 15, 2019
Androgen deprivation therapy for prostate cancer and risk of dementiaDavid Robinson, Hans Garmo, Mieke Van Hemelrijck, et al.
BMC Molecular and Cell Biology|July 25, 2019
Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysisAida Santaolalla, Hans Garmo, Anita Grigoriadis, et al.
Gut|October 23, 2012
Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008Victoria H Coupland, Jesper Lagergren, Margreet Lüchtenborg, et al.
British Journal of Cancer|October 16, 2015
Serum lactate dehydrogenase and survival following cancer diagnosisWahyu Wulaningsih, Lars Holmberg, Hans Garmo, et al.
Pageof 29

Showing results (171-180 of 287) with videos related to

Sort By:
Pageof 29
BMJ Open|December 29, 2022
Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort studyMats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, et al.
British Journal of Haematology|July 14, 2007
Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpuraMinola Manea, AnnCharlotte Kristoffersson, Reinhard Schneppenheim, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Epidemiology (Cambridge, Mass.)|May 3, 2021
An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate CohortsRolf Gedeborg, Malin Sund, Mats Lambe, et al.
Ecancermedicalscience|February 20, 2018
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitusDanielle Crawley, Florence Chamberlain, Hans Garmo, et al.
BJU International|January 15, 2019
Androgen deprivation therapy for prostate cancer and risk of dementiaDavid Robinson, Hans Garmo, Mieke Van Hemelrijck, et al.
BMC Molecular and Cell Biology|July 25, 2019
Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysisAida Santaolalla, Hans Garmo, Anita Grigoriadis, et al.
Gut|October 23, 2012
Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008Victoria H Coupland, Jesper Lagergren, Margreet Lüchtenborg, et al.
British Journal of Cancer|October 16, 2015
Serum lactate dehydrogenase and survival following cancer diagnosisWahyu Wulaningsih, Lars Holmberg, Hans Garmo, et al.
Pageof 29